{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:22:33Z","timestamp":1791408153457,"version":"4.3.3"},"reference-count":91,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pheochromocytomas and paragangliomas (PPGLs) are rare tumors of the adrenal and extra-adrenal chromaffin cells. Although most PPGLs remain localized, approximately 25% develop metastatic disease (MPPGL), leading to substantial morbidity due to tumor burden and catecholamine excess. These tumors have a heterogeneous biologic activity, with some having an aggressive course requiring intensive treatment, and others behaving indolently, not requiring treatment over many years. Because there are no sufficiently accurate predictors of future behavior, all PPGLs are considered to have the potential for metastatic disease.<\/jats:p>\n                  <jats:p>Over the past decade, the treatment landscape for MPPGL has evolved dramatically. In addition to cytotoxic chemotherapy with cyclophosphamide, vincristine, and dacarbazine, several targeted radiopharmaceuticals have shown activity against MPPGL. Furthermore, multi-target tyrosine kinase inhibitors, including sunitinib and cabozantinib, have demonstrated substantial disease control in prospective clinical trials. Most notably, belzutifan, a hypoxia-inducible factor-2\u03b1 inhibitor, recently became the first oral therapy approved by the US Food and Drug Administration for MPPGL, demonstrating durable responses, improvement in hypertension, and preservation of quality of life.<\/jats:p>\n                  <jats:p>In this review, we highlight an illustrative case of MPPGL and provide a contemporary framework of the treatment landscape. We also present an algorithm that integrates clinical phenotype and tumor genotype to advise which systemic therapies may benefit individual patients with MPPGL. As therapeutic options continue to expand, we emphasize the role of multidisciplinary management as essential in the treatment of these rare and biologically complex malignancies.<\/jats:p>","DOI":"10.1210\/clinem\/dgag182","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:32:19Z","timestamp":1776771139000},"page":"2389-2402","source":"Crossref","is-referenced-by-count":4,"title":["Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy"],"prefix":"10.1210","volume":"111","author":[{"given":"Michael","family":"Glover","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Waguespack","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaan","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-3355","authenticated-orcid":false,"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"1","key":"2026071419570926700_dgag182-B1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"13","key":"2026071419570926700_dgag182-B2","doi-asserted-by":"crossref","first-page":"13942","DOI":"10.1002\/cam4.6010","article-title":"Management of pheochromocytomas and paragangliomas: review of current diagnosis and treatment options","volume":"12","author":"Eid","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"2026071419570926700_dgag182-B3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"issue":"6","key":"2026071419570926700_dgag182-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101958","article-title":"Recent progress in the pathologic classification of pheochromocytomas and paragangliomas","volume":"38","author":"Mete","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2026071419570926700_dgag182-B5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgac677","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","volume":"108","author":"Jimenez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419570926700_dgag182-B6","volume-title":"AJCC cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"3","key":"2026071419570926700_dgag182-B7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2026071419570926700_dgag182-B8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"2026071419570926700_dgag182-B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2025.101977","article-title":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"39","author":"Fischer","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2026071419570926700_dgag182-B10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"2026071419570926700_dgag182-B11","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026071419570926700_dgag182-B12","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419570926700_dgag182-B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114122","article-title":"Adverse skeletal related events in patients with bone-metastatic pheochromocytoma\/paraganglioma","volume":"208","author":"Lagana","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"2026071419570926700_dgag182-B14","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419570926700_dgag182-B15","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"European network for the study of adrenal T. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419570926700_dgag182-B16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"2026071419570926700_dgag182-B17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"issue":"13","key":"2026071419570926700_dgag182-B18","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","article-title":"TET-Mediated Hypermethylation primes SDH-deficient cells for HIF2alpha-driven mesenchymal transition","volume":"30","author":"Morin","year":"2020","journal-title":"Cell Rep"},{"issue":"24","key":"2026071419570926700_dgag182-B19","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1093\/hmg\/ddm275","article-title":"Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma","volume":"16","author":"Smith","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2026071419570926700_dgag182-B20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026071419570926700_dgag182-B21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12022-024-09830-3","article-title":"The molecular classification of pheochromocytomas and paragangliomas: discovering the genomic and immune landscape of metastatic disease","volume":"35","author":"de Bresser","year":"2024","journal-title":"Endocr Pathol"},{"issue":"1","key":"2026071419570926700_dgag182-B22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13148-023-01598-3","article-title":"A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide","volume":"15","author":"Chatzikyriakou","year":"2023","journal-title":"Clin Epigenetics"},{"issue":"5","key":"2026071419570926700_dgag182-B23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"28","key":"2026071419570926700_dgag182-B24","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1200\/JCO-25-00791","article-title":"Phase II study of (177)Lu-DOTATATE for progressive metastatic pheochromocytomas and paragangliomas: interim analysis of efficacy, safety, and biomarkers","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10431","key":"2026071419570926700_dgag182-B25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"2026071419570926700_dgag182-B26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the natalie trial): a single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol"},{"issue":"20","key":"2026071419570926700_dgag182-B27","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"2026071419570926700_dgag182-B28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2026071419570926700_dgag182-B29","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"2026071419570926700_dgag182-B30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"issue":"11","key":"2026071419570926700_dgag182-B31","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"2026071419570926700_dgag182-B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"issue":"2","key":"2026071419570926700_dgag182-B33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-010-9422-5","article-title":"Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center","volume":"39","author":"Szalat","year":"2011","journal-title":"Endocrine"},{"key":"2026071419570926700_dgag182-B34","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3332\/ecancer.2023.1523","article-title":"Metastatic pheochromocytoma and paraganglioma: a retrospective multicentre analysis on prognostic and predictive factors to chemotherapy","volume":"17","author":"Pacheco","year":"2023","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"2026071419570926700_dgag182-B35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026071419570926700_dgag182-B36","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","author":"Jasim","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2026071419570926700_dgag182-B37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-15-0456","article-title":"Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma","volume":"173","author":"Thosani","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026071419570926700_dgag182-B38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment","volume":"2016","author":"van Leeuwen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2026071419570926700_dgag182-B39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"2026071419570926700_dgag182-B40","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026071419570926700_dgag182-B41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-022-01197-0","article-title":"New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an American, contemporary, pragmatic approach","volume":"24","author":"Jimenez","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2026071419570926700_dgag182-B42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1066208","article-title":"The use of temozolomide in paediatric metastatic phaeochromocytoma\/paraganglioma: a case report and literature review","volume":"13","author":"Urquhart","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026071419570926700_dgag182-B43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026071419570926700_dgag182-B44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2026071419570926700_dgag182-B45","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"9","key":"2026071419570926700_dgag182-B46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-21-0392","article-title":"SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma","volume":"29","author":"Perez","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2026071419570926700_dgag182-B47","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026071419570926700_dgag182-B48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"25","key":"2026071419570926700_dgag182-B49","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026071419570926700_dgag182-B50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419570926700_dgag182-B51","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0236","article-title":"Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma\/paraganglioma","volume":"30","author":"Jimenez","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2026071419570926700_dgag182-B52","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/RLU.0000000000005184","article-title":"High-specific-activity 131 I-MIBG for the treatment of advanced pheochromocytoma and paraganglioma","volume":"49","author":"Al-Ward","year":"2024","journal-title":"Clin Nucl Med"},{"key":"2026071419570926700_dgag182-B53","first-page":"C20","article-title":"Quality of life assessments for advanced pheochromocytoma and paraganglioma patients that received high-specific-activity I-131 MIBG: results from a pivotal phase 2 clinical trial","volume":"89","author":"Jimenez","year":"2023","journal-title":"Endocrine Abstracts"},{"issue":"10","key":"2026071419570926700_dgag182-B54","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2026071419570926700_dgag182-B55","article-title":"Managing catecholamine release syndrome during and following lu-177-DOTATATE in high-risk pheochromocytoma patients","volume":"2","author":"Phelps","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"10","key":"2026071419570926700_dgag182-B56","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1507\/endocrj.EJ24-0713","article-title":"Potentially fatal crisis after (177)Lu-DOTATATE therapy for paraganglioma: a case report with review of literature","volume":"72","author":"Tobimatsu","year":"2025","journal-title":"Endocr J"},{"issue":"4","key":"2026071419570926700_dgag182-B57","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"de Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2026071419570926700_dgag182-B58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor Lysis syndrome and the need for modification of treatment protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"2026071419570926700_dgag182-B59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114230","article-title":"Challenges of estimating treatment effects after a positive interim analysis","volume":"209","author":"Soon","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"2026071419570926700_dgag182-B60","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with (177)Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"2026071419570926700_dgag182-B61","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"issue":"4","key":"2026071419570926700_dgag182-B62","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.3390\/ijms15045323","article-title":"Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma","volume":"15","author":"Ferreira","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026071419570926700_dgag182-B63","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane","year":"2019","journal-title":"Br J Cancer"},{"issue":"3","key":"2026071419570926700_dgag182-B64","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","article-title":"Clinical activity of selpercatinib in RET-mutant pheochromocytoma","volume":"110","author":"Deschler-Baier","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419570926700_dgag182-B65","article-title":"Lenvatinib as a therapeutic option in unresectable metastatic pheochromocytoma and paragangliomas","volume":"6","author":"Nelson L","year":"2022","journal-title":"J Endocr Soc"},{"issue":"7","key":"2026071419570926700_dgag182-B66","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026071419570926700_dgag182-B67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12022-025-09890-z","article-title":"The utility of cabozantinib in the therapy of endocrine tumours","volume":"36","author":"Armeni","year":"2025","journal-title":"Endocr Pathol"},{"issue":"12","key":"2026071419570926700_dgag182-B68","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"2026071419570926700_dgag182-B69","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/oncolo\/oyac083","article-title":"Phase II study of cabozantinib in patients with bone metastasis","volume":"27","author":"Choy","year":"2022","journal-title":"Oncologist"},{"issue":"10","key":"2026071419570926700_dgag182-B70","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026071419570926700_dgag182-B71","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ymthe.2018.05.004","article-title":"Differential but complementary HIF1alpha and HIF2alpha transcriptional regulation","volume":"26","author":"Downes","year":"2018","journal-title":"Mol Ther"},{"issue":"2","key":"2026071419570926700_dgag182-B72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2alpha) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"issue":"13","key":"2026071419570926700_dgag182-B73","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-20-2936","article-title":"Loss of SDHB promotes dysregulated iron homeostasis, oxidative stress, and sensitivity to ascorbate","volume":"81","author":"Goncalves","year":"2021","journal-title":"Cancer Res"},{"issue":"32","key":"2026071419570926700_dgag182-B74","doi-asserted-by":"crossref","first-page":"32955","DOI":"10.18632\/oncotarget.5106","article-title":"Deciphering the molecular basis of invasiveness in SDHB-deficient cells","volume":"6","author":"Loriot","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2026071419570926700_dgag182-B75","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"2026071419570926700_dgag182-B76","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/onc.2015.172","article-title":"Rethinking pheochromocytomas and paragangliomas from a genomic perspective","volume":"35","author":"Castro-Vega","year":"2016","journal-title":"Oncogene"},{"issue":"13","key":"2026071419570926700_dgag182-B77","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1158\/1078-0432.CCR-14-2804","article-title":"DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers","volume":"21","author":"de Cubas","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2026071419570926700_dgag182-B78","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2alpha inhibitor, in the Pacak-Zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2026071419570926700_dgag182-B79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eprac.2025.09.204","article-title":"Belzutifan for HIF2A-related pheochromocytoma and paraganglioma: a retrospective study of real-world data","volume":"32","author":"Alkaissi","year":"2025","journal-title":"Endocr Pract"},{"issue":"22","key":"2026071419570926700_dgag182-B80","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2026071419570926700_dgag182-B81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(25)00032-4","article-title":"Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial","volume":"26","author":"Powles","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026071419570926700_dgag182-B82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026071419570926700_dgag182-B83","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2026071419570926700_dgag182-B84","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1158\/1078-0432.CCR-25-2143","article-title":"Cabozantinib plus atezolizumab in advanced, progressive endocrine malignancies: a multicohort, basket, phase II trial (CABATEN\/GETNE-T1914)","volume":"31","author":"Capdevila","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026071419570926700_dgag182-B85","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/cancers14030467","article-title":"Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: do they work?","volume":"14","author":"Jimenez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026071419570926700_dgag182-B86","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1433582","article-title":"Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment","volume":"15","author":"Saavedra","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026071419570926700_dgag182-B87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1507\/endocrj.EJ25-0165","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of pheochromocytoma and paraganglioma 2025","volume":"73","author":"Tanabe","year":"2026","journal-title":"Endocr J"},{"issue":"1","key":"2026071419570926700_dgag182-B88","article-title":"Massive pheochromocytomatosis treated with cytoreductive surgery","volume":"4","author":"Carling","year":"2026","journal-title":"JCEM Case Rep"},{"key":"2026071419570926700_dgag182-B89","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1679629","article-title":"Peritoneal implantation of pheochromocytoma - pheochromocytomatosis: a case report and mini review","volume":"16","author":"Benyei","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026071419570926700_dgag182-B90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00104-019-01070-0","article-title":"Pheochromocytomatosis after adrenalectomy: metastasis or cell seeding?","volume":"91","author":"Weber","year":"2020","journal-title":"Chirurg"},{"issue":"3","key":"2026071419570926700_dgag182-B91","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ccr3.498","article-title":"Local recurrence of pheochromocytoma in multiple endocrine neoplasia type 2A: a diagnostic and therapeutic challenge","volume":"4","author":"Tramunt","year":"2016","journal-title":"Clin Case Rep"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag182\/68144547\/dgag182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/2389\/68144547\/dgag182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/8\/2389\/68144547\/dgag182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:57:29Z","timestamp":1784073449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/8\/2389\/8661545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":91,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag182","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,22]]}}}